These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 26071333

  • 1. Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: A single centre, prospective cohort study.
    Durante-Mangoni E, Andini R, Pinto D, Iossa D, Molaro R, Agrusta F, Casillo R, Grimaldi M, Utili R.
    J Clin Virol; 2015 Jul; 68():37-42. PubMed ID: 26071333
    [Abstract] [Full Text] [Related]

  • 2. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.
    Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
    [Abstract] [Full Text] [Related]

  • 3. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK, Pouch SM, Kissling KT.
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus infection in renal transplant recipients: one center's experience.
    Bal Z, Uyar ME, Tutal E, Erdogan E, Colak T, Sezer S, Haberal M.
    Transplant Proc; 2013 Nov; 45(10):3520-3. PubMed ID: 24314948
    [Abstract] [Full Text] [Related]

  • 5. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients.
    Grossi P, Minoli L, Percivalle E, Irish W, Vigano M, Gerna G.
    Transplantation; 1995 Mar 27; 59(6):847-51. PubMed ID: 7701579
    [Abstract] [Full Text] [Related]

  • 6. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS, Romano G, Mastroianni C, Roberta C, Della Corte A, Amarelli C, Maiello C, Giannolo B, Marra C, Ragone E, Grimaldi M, Utili R, Scardone M, Cotrufo M.
    Transplant Proc; 2005 Mar 27; 37(6):2684-7. PubMed ID: 16182784
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, Husain S, Paterson DL, Chiller T, Pappas P.
    Transpl Infect Dis; 2018 Jun 27; 20(3):e12877. PubMed ID: 29512935
    [Abstract] [Full Text] [Related]

  • 8. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 9. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA, Brennan DC, Yusen RD, Olsen MA.
    Transplantation; 2015 Aug 15; 99(8):1658-66. PubMed ID: 25675196
    [Abstract] [Full Text] [Related]

  • 10. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 15; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 11. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 12. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years.
    Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV.
    Transplantation; 2005 May 27; 79(10):1428-34. PubMed ID: 15912115
    [Abstract] [Full Text] [Related]

  • 13. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.
    Mendez-Eirin E, Paniagua-Martín MJ, Marzoa-Rivas R, Barge-Caballero E, Grille-Cancela Z, Cañizares A, Naya-Leira C, Gargallo-Fernández P, Castro-Beiras A, Crespo-Leiro M.
    Transplant Proc; 2012 Nov 27; 44(9):2660-2. PubMed ID: 23146486
    [Abstract] [Full Text] [Related]

  • 14. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug 27; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology of cytomegalovirus infection after pancreas transplantation.
    Parsaik AK, Bhalla T, Dong M, Rostambeigi N, Dierkhising RA, Dean P, Abraham R, Prieto M, Kremers WK, Razonable RR, Kudva YC.
    Transplantation; 2011 Nov 15; 92(9):1044-50. PubMed ID: 21904269
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R, Grimaldi M, Ragone E, Maiello C, Marra C, De Santo L, Amarelli C, Romano G, Della Corte A, Portella G, Tripodi MF, Fortunato R, Cotrufo M, Utili R.
    Transplant Proc; 2004 Apr 15; 36(3):651-3. PubMed ID: 15110622
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
    Puttarajappa C, Bhattarai M, Mour G, Shen C, Sood P, Mehta R, Shah N, Tevar AD, Humar A, Wu C, Hariharan S.
    Clin Transplant; 2016 Sep 15; 30(9):1159-64. PubMed ID: 27423138
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology and risk factors for late infection in solid organ transplant recipients.
    Cervera C, Fernández-Ruiz M, Valledor A, Linares L, Antón A, Ángeles Marcos M, Sanclemente G, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Pumarola T, Moreno A.
    Transpl Infect Dis; 2011 Dec 15; 13(6):598-607. PubMed ID: 21535336
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A.
    Liver Transpl; 2012 Dec 15; 18(12):1448-55. PubMed ID: 22903934
    [Abstract] [Full Text] [Related]

  • 20. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C, Pérez-Romero P, Blanco-Lobo P, Benmarzouk-Hidalgo OJ, Sánchez M, Gentil MA, Bernal C, Sobrino JM, Rodríguez-Hernández MJ, Cordero E, Spanish Network for Research in Infectious Diseases (REIPI).
    Transpl Int; 2014 Oct 15; 27(10):1060-8. PubMed ID: 24964364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.